Responses
Regular and Young Investigator Award Abstracts
Combination Immunotherapies
596 Combining Bempegaldesleukin (CD122-preferential IL-2 pathway agonist) and NKTR-262 (TLR7/8 agonist) pairs local innate activation with systemic CD8+ T cell expansion to enhance anti-tumor immunity
Compose a Response to This Article
Other responses
No responses have been published for this article.